Avanos stock holds steady as investors weigh recent earnings and guidance

Avanos Medical Inc. (ISIN US05350V1061) is a US based medical technology company focused on minimally invasive solutions, and Avanos stock currently trades at a level that reflects investors’ cautious assessment of its recent earnings and guidance. As of 30 April 2026, Avanos had a market capitalization of approximately $1.00 billion according to public market data, placing it among mid cap medical device peers and giving investors a clear sense of scale in the sector.

Revenue trends and margin pressures

In its results for fiscal 2025, Avanos reported annual revenue of roughly $675 million, according to figures summarized from recent investor materials. This revenue level was broadly in line with the prior year period, when Avanos generated about $670 million in fiscal 2024, indicating year over year growth of around 0.7%. The modest increase highlights a business that is stabilizing after portfolio changes and strategic refocusing, but the narrow revenue growth also means investors are closely watching operating efficiency.

Operating profit and margins have been under scrutiny as Avanos continues to invest in innovation and commercial capabilities. For fiscal 2025, adjusted EBITDA was approximately $110 million compared with about $115 million in fiscal 2024, implying a decrease of $5 million or around 4.3% year over year. This decline in EBITDA, despite slightly higher revenue, suggests margin compression driven by mix effects, inflation in input costs, or higher selling and R&D expenses. For investors, the relationship between revenue growth and margin trends is central to evaluating Avanos stock over the medium term.

Guidance and earnings per share

Management guidance has also shaped expectations for Avanos stock. In an outlook communicated for fiscal 2026, Avanos indicated a revenue range of $680 million to $700 million, implying potential growth of roughly 0.7% to 3.7% over the reported fiscal 2025 revenue of $675 million. This guidance band signals that the company expects continued but measured expansion, supported by new products and focus areas within its portfolio.

On the bottom line, diluted earnings per share (EPS) on an adjusted basis for fiscal 2025 stood around $1.10, compared with approximately $1.20 in fiscal 2024. The $0.10 decline in adjusted EPS represents a drop of about 8.3% year over year, and reflects the same operating cost pressures that weighed on EBITDA. Investors often compare this EPS trajectory with broader medical device peers, where mid single digit to double digit EPS growth is common in stronger cycles, to judge whether Avanos can close the growth gap with operational improvements.

Balloon catheter portfolio in pain management

Avanos has built a notable presence in pain management through its radiofrequency and nerve block solutions, including balloon catheters and related devices for chronic pain procedures. These products are designed to help physicians deliver targeted treatment while minimizing invasiveness, aligning with healthcare systems’ emphasis on outpatient care and reduced hospital stays. In 2025, pain management solutions accounted for an estimated $250 million of Avanos revenue, roughly 37% of the total, based on management commentary and segment disclosures; that share underlines the strategic weight of this portfolio for long term growth.

Within pain management, balloon catheters and nerve ablation technologies have seen steady demand from interventional pain specialists, especially in markets where reimbursement frameworks support minimally invasive alternatives to open surgery. The segment’s revenue grew by about 3% in 2025 compared with 2024, rising from around $243 million to $250 million. This growth rate outpaced the broader company average, suggesting that investors looking at Avanos stock may view pain devices as a relative bright spot within the portfolio, even as other business lines adjust to changing hospital purchasing patterns.

Avanos stock valuation and trading context

Avanos stock is listed on the New York Stock Exchange and trades in US dollars, giving it access to a broad base of institutional and retail investors who follow US healthcare names. As of 30 April 2026, the share price was approximately $25.00 on the NYSE, according to consolidated quote data, placing the stock near the midpoint of its observed 52 week range between about $20.00 and $30.00. That range implies a spread of $10.00 between low and high, or around 50% of the low price, which investors sometimes use as a quick signal of volatility and sentiment shifts over the year.

At the $25.00 share price and the roughly $1.10 in adjusted EPS for fiscal 2025, Avanos trades at an implied price to earnings multiple near 22.7 times, using simple division. This valuation compares with mid to high teens multiples for some larger diversified medical device companies, and suggests the market is pricing Avanos stock with a premium for potential growth in pain management and infection prevention, while still reflecting the risks of moderate revenue growth and margin compression. For yield oriented investors, it is also relevant that Avanos has not been known for a high dividend payout; instead, cash flow has tended to support reinvestment and occasional balance sheet strengthening.

Balance sheet metrics provide another lens. At the end of fiscal 2025, Avanos reported net debt of roughly $150 million, including lease liabilities, compared with about $170 million at the end of fiscal 2024. The $20 million reduction represents an improvement of about 11.8%, signaling progress in deleveraging as free cash flow covers interest, principal, and capital expenditure needs. With adjusted EBITDA around $110 million in 2025, the net leverage ratio sits close to 1.4 times, a level that most investors would consider manageable for a mid cap medical technology company, and that leaves room for disciplined acquisitions or targeted R&D investment.

Product focus and hospital adoption

Beyond pain management catheters, Avanos markets a range of enteral feeding, respiratory health, and infection prevention products, many of which stem from legacy medical device portfolios that have been refined over time. Hospitals have increasingly focused on devices that can shorten procedure times, reduce complications, and fit into standardized care pathways; this environment favors vendors like Avanos that offer clinically validated solutions and training support. In fiscal 2025, infection prevention products, including closed suction systems and catheter securement devices, generated about $210 million in revenue, up from roughly $205 million in 2024, a 2.4% increase that reflects steady demand rather than surge growth.

In the US and selected international markets, Avanos has also pursued digital tools and service models to support its devices, such as remote training modules and procedure data tracking for quality improvement initiatives. While these initiatives do not yet represent material revenue lines on their own, they can strengthen customer relationships and support future upgrades or cross selling across the catheter, pain, and infection prevention portfolios. For investors considering the long term trajectory of Avanos stock, these service elements may help differentiate the company from pure hardware competitors with limited clinical support infrastructure.

Avanos stock price and market perception

From a trading perspective, Avanos stock at $25.00 as of 30 April 2026 sits closer to the upper half of its 52 week band, though below the $30.00 high, indicating that investors have rewarded recent progress on revenue stability and debt reduction without fully repricing the shares to the top of the range. Daily average volume in early 2026 has hovered around 300,000 shares, providing adequate liquidity for most retail and smaller institutional investors while still leaving the stock sensitive to larger block trades.

Analyst coverage for Avanos remains moderate relative to mega cap healthcare names, with a handful of brokerages publishing estimates and ratings that typically cluster around neutral to moderately positive views. Consensus models for fiscal 2026, for example, have pointed to EPS in the $1.15 to $1.25 range, which would represent year over year growth of roughly 4.5% to 13.6% compared with the $1.10 adjusted EPS reported for 2025. If the company can deliver toward the upper end of that EPS range while maintaining revenue growth within the guided $680 million to $700 million band, investors might consider the current valuation reasonable; if not, the price to earnings multiple could face pressure.